IN THE CLAIMS:

1. (Currently amended) A pharmaceutical formulation comprising an active compound having the structural formula



wherein said compound is provided as free drug comprising particles wherein at least 90% of the particles have a particle size of less than about 40 microns; a water-soluble diluent; a lubricant; a hydrophilic binder selected from the group consisting of a cellulose derivative, povidone, and a mixture thereof; and a disintegrant selected from the group consisting of croscarmellose sodium, crospovidone, and a mixture thereof.

2. (Original) The formulation of claim 1 further comprising microcrystalline cellulose.

3. (Original) The formulation of claim 1 further comprising a wetting agent.

4. (Original) The formulation of claim 1 wherein the active compound is present in an amount of about 0.5% to about 10% by weight.

5. (Original) The formulation of claim 1 wherein the water-soluble diluent is present in an amount of about 50% to about 85% by weight.

6. (Original) The formulation of claim 1 wherein the water-soluble diluent is selected from the group consisting of a sugar, a polysaccharide, a polyol, a cyclodextrin, and mixtures thereof.

7. (Currently amended) The formulation of claim ~~3~~ 1 wherein the water-soluble diluent is selected from the group consisting of lactose, sucrose, dextrose, a dextrate, a maltodextrin, mannitol, xylitol, sorbitol, a cyclodextrin, and mixtures thereof.

8. (Original) The formulation of claim 1 wherein the lubricant is present in an amount of about 0.25% to about 2% by weight.

9. (Original) The formulation of claim 1 wherein the lubricant is selected from the group consisting of talc, magnesium stearate, calcium stearate, stearic acid, colloidal silicon dioxide, calcium silicate, a starch, mineral oil, a wax, glyceryl behenate, a polyethylene glycol, sodium benzoate, sodium acetate, sodium stearyl fumarate, hydrogenated vegetable oils, and mixtures thereof.

10. (Original) The formulation of claim 1 wherein the hydrophilic binder is present in an amount of about 1% to about 5% by weight.

11. (Original) The formulation of claim 1 wherein the cellulose derivative is selected from the group consisting of hydroxypropylcellulose, hydroxypropyl methylcellulose, and mixtures thereof.

12. (Original) The formulation of claim 1 wherein the disintegrant is present in an amount of about 3% to about 10% by weight.

13. (Original) The formulation of claim 2 wherein the microcrystalline cellulose is present in an amount of about 5% to about 40% by weight.

14. (Original) The formulation of claim 3 wherein the wetting agent is present in an amount of 0.1% to about 5% by weight.

15. (Original) The formulation of claim 14 wherein the wetting agent is selected from the group consisting of sodium lauryl sulfate, docusate sodium, ethoxylated castor oil, a polyglycolyzed glyceride, an acetylated monoglyceride, a sorbitan fatty acid ester, a poloxamer, a polyoxyethylene sorbitan fatty acid ester, a polyoxyethylene, a monoglyceride and ethoxylated derivatives thereof, a diglyceride and ethoxylated derivatives thereof, and mixtures thereof.

16. (Currently amended) The formulation of claim ~~1~~ 15 wherein the wetting agent is selected from the group consisting of sodium lauryl sulfate, polysorbate 80, and a mixture thereof.

17. (Cancelled)

18. (Original) The formulation of claim 1 wherein the active compound is provided as particles of a free drug wherein at least 90% of the particles have a particle size less than about 10 microns.

19. (Original) The formulation of claim 1 comprising:

(a) about 1% to about 4% by weight of the active compound;

(b) about 50% to about 75% by weight lactose;

(c) about 0.25% to about 2% by weight magnesium stearate;

(d) about 1% to about 5% by weight hydroxypropyl cellulose; and

(e) about 3% to about 10% by weight croscarmellose sodium.

20. (Original) The formulation of claim 18 further comprising about 5% to about 40% by weight microcrystalline cellulose.

21. (Original) The formulation of claim 18 further comprising about 0.1% to about 5% by weight sodium lauryl sulfate.

22. (Original) A tablet comprising the formulation of claim 1 wherein the active compound is present in an amount of about 1 to about 20 mg per tablet.

23. (Original) A tablet comprising the formulation of claim 1 wherein the active compound is present in an amount of about 5 to about 15 mg per tablet.

24. (Currently amended) A tablet comprising the formulation of claim 1 wherein the active compound is present in an amount of about 5 mg ~~or about 10 mg~~ per tablet.

25. (Original) A capsule comprising a hard shell encasing the formulation of claim 1 as dry, free-flowing particles, wherein the active compound is present in an amount of about 1 to about 20 mg per capsule.

26. (Cancelled)

27. (Cancelled)

28. (New) The formulation of claim 1 wherein the active compound is provided as particles of a free drug wherein at least 90% of the particles have a particle size less than about 30 microns.

29. (New) The formulation of claim 1 wherein the active compound is provided as particles of a free drug wherein at least 90% of the particles have a particle size less than about 25 microns.

30. (New) The formulation of claim 1 wherein the active compound is provided as particles of a free drug wherein at least 90% of the particles have a particle size less than about 15 microns.

31. (New) A tablet comprising the formulation of claim 1 wherein the active compound is present in an amount of about 10 mg per tablet.

32. (New) A tablet comprising the formulation of claim 1 wherein the active compound is present in an amount of about 1 to about 5 mg per tablet.

33. (New) A tablet comprising the formulation of claim 1 wherein the active compound is present in an amount of about 2.5 mg per tablet.

34. (New) A tablet comprising the formulation of claim 1 wherein the active compound is present in an amount of about 20 mg per tablet.

35. (New) A method of treating sexual dysfunction in a patient in need thereof comprising administering to the patient an effective amount of a formulation or a tablet according to of any one of claims 1 through 25 or claims 28 through 30.

36. (New) The method of claim 35 wherein the sexual dysfunction is male erectile dysfunction.

37. (New) A pharmaceutical formulation comprising an active compound having the structural formula



wherein said compound is provided as free drug comprising particles wherein at least 90% of the particles have a particle size of less than about 40 microns; a water-soluble diluent, a lubricant; a hydrophilic binder; and a disintegran.